Creatine increases hippocampal Na+,K+-ATPase activity via NMDA–calcineurin pathway  by Rambo, Leonardo Magno et al.
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Achievements  made  over  the  past  few  years  have  demonstrated  the  important  role  of the  creatine  and
phosphocreatine  system  in  the  buffering  and  transport  of  high-energy  phosphates  into  the  brain;  how-
ever,  the  non-energetic  processes  elicited  by this  guanidine  compound  in  the  hippocampus  are still  poorly
understood.  In the  present  study  we  disclosed  that  the  incubation  of  rat  hippocampal  slices  with  creatine
(10 mM)  for  30 min  increased  Na+,K+-ATPase  activity.  In addition,  intrahippocampal  injection of  creatine
(5  nmol/site)  also  increased  the  above-mentioned  activity.  The  incubation  of  hippocampal  slices  with
N-methyl-d-aspartate  (NMDA;  MK-801,  10 M) and  NMDA  Receptor  2B  (NR2B;  ifenprodil,  3  M)  antago-
nists  but  not  with  the  -amino-3-hydroxy-5-methyl-4-isoxazolepropionic  acid  receptor  (AMPA)/kainate
antagonist  (DNQX,  10 M)  and  nitric  oxide  synthase  inhibitor  (NOS;  l-NAME,  100  M), blunted  the effect
of  creatine  on  Na+,K+-ATPase  activity.  Furthermore,  the  calcineurin  inhibitor  (cyclosporine  A,  200  nM)
as well  as  the Protein  Kinase  C (PMA,  100  nM)  and  Protein  Kinase  A (8-Br-cAMP,  30 M)  activators
+ +attenuated  the creatine-induced  increase  of  Na ,K -ATPase  activity.  In addition,  the  incubation  of  hip-
pocampal  slices  with  creatine  (10 mM)  for 30 min  increased  calcineurin  activity.  The  results  presented
here  suggest  that  creatine  increases  Na+,K+-ATPase  activity  via  NMDA–calcineurin  pathway,  proposing  an
putative  underlying  non-energetic  role of  this  guanidine  compound.  However,  more  studies  are needed
to assess  the  contribution  of this  putative  alternative  role  in  neurological  diseases  that  present  decreased
Na+,K+-ATPase  activity.. Introduction
Creatine (N-[aminoiminomethyl]-N-methyl glycine) is a guani-
ine compound synthesized in the kidneys, liver, pancreas, and
rain or obtained from alimentary sources like meat and fresh
sh (Wyss and Kaddurah-Daouk, 2000). Experimental and clinical
ndings indicate that creatine-induced high-energy phosphate
aintenance protects against ATP depletion in a number of
athological conditions including Alzheimer’s (Burklen et al.,
006), Parkinson’s (Bender et al., 2006, 2008) and Huntington’s
iseases (Ferrante et al., 2000; Hersch et al., 2006; Ryu et al.,
∗ Corresponding author at: Departamento de Métodos e Técnicas Desportivas,
entro de Educac¸ ão Física e Desportos, Universidade Federal de Santa Maria, 97105-
00 Santa Maria, RS, Brazil. Tel.: +55 55 3220 9378; fax: +55 55 3220 8031.
E-mail address: nandoroyes@yahoo.com.br (L.F.F. Royes).
361-9230     © 2012 Elsevier Inc.  
ttp://dx.doi.org/10.1016/j.brainresbull.2012.06.007
Open access under the Elsevier OA license.© 2012 Elsevier Inc. 
2005); amyotrophic lateral sclerosis (Ellis and Rosenfeld, 2004;
Rosenfeld et al., 2008; Shefner et al., 2004), and traumatic brain
injury (Sullivan et al., 2000; Sakellaris et al., 2006; Scheff and
Dhillon, 2004). Although there is the notion that the mechanisms
of neuronal function improvement and neuroprotection exerted
by creatine include enhanced energy buffering, a non-energetic
neuromodulatory role for creatine has also been proposed (Persky
and Brazeau, 2001). Creatine is not only synthesized and taken
up by neurons, but that it is also released in an action-potential-
dependent manner (Almeida et al., 2006). Furthermore, the bath
application of creatine increases both amplitude and number of
population spike in the stratum radiatum of the hippocampal
CA1 subﬁeld, an effect reverted by the selective NMDA  receptor
Open access under the Elsevier OA license.antagonist 2-amino-5-phosphonopentanoic acid (AP5) (Royes
et al., 2008). In line with this view, creatine increases [3H]MK-801
binding to hippocampal membranes by 55% (Royes et al., 2008)
and leads to spatial learning improvement, possibly by modulating
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olyamine binding site at the NMDA receptor (Oliveira et al.,
008). However, the downstream effectors of the creatine-induced
odulation of the NMDA receptor are still unknown.
NMDA receptors stimulation leads to the activation of Na+,K+-
TPase (Marcaida et al., 1996; Munhoz et al., 2005; Bersier et al.,
008), a key enzyme involved in the transmembranal transport
f sodium and potassium which plays a pivotal role in the cel-
ular ionic gradient maintenance (Skou and Esmann, 1992) and
ay  be modulated by a complex and not completely understood
hosphorylation cascade of regulatory proteins. PKA activators,
uch as forskolin and Sp-5,6-DCI-cBIMPS - as well as the PKC
ctivator phorbol 12,13-dibutyrate – signiﬁcantly reduce Na+,K+-
TPase activity in neurons or COS cells (Cheng et al., 1999, 1997a,b;
ishi et al., 1999a). On the other hand, -adrenergic as well
s NMDA receptor activation increases Na+,K+-ATPase activity
hrough the activation of the calcium-dependent protein phos-
hatase 2B, calcineurin (Aperia et al., 1992; Marcaida et al., 1996).
he glutamate-induced calcineurin activation counteracts the PKC-
ediated phosphorylation of Na+,K+-ATPase leading to an increase
f pump activity (Marcaida et al., 1996).
In this research we take into account that creatine may  play
 putative role as a neuromodulator in the brain (Almeida et al.,
006). In this sense, previous works from our group suggest that
reatine may  modulate brain NMDA receptors (Royes et al., 2008;
liveira et al., 2008). Furthermore, in the same way, there are data
n literature showing that glutamatergic agonists increase Na+,K+-
TPase activity in cultured neurons (Inoue et al., 1999). Therefore,
e decided to investigate whether creatine alters Na+,K+-ATPase
ctivity in rat hippocampal slices. Moreover, given that PKA,
KC and calcineurin are major downstream kinases/phosphatases
nvolved in the Na+,K+-ATPase activity regulation (Cheng et al.,
999; Nishi et al., 1999a,b), we also investigated the effect of
reatine on calcineurin activity and whether those pathways are
nvolved in the effect exerted by creatine on Na+,K+-ATPase activity.
. Materials and methods
.1. Animals and reagents
Adult male Wistar rats (250–300 g) maintained under controlled light and envi-
onment (12 h light/dark cycle, 24 ± 1 ◦C, 55% relative humidity) with free access to
ood and water were used. Animal utilization reported in this study was conducted
n accordance with the policies of the National Institutes of Health Guide for the Care
nd Use of Laboratory Animals (NIH Publication No. 80-23, revised in 1996) and with
he Institutional and National regulations for animal research. All efforts were made
o  reduce the number of animals used, as well as to minimize their suffering.
Phorbol 12-myristate 13-acetate (PMA) was dissolved in 100% ethanol and
hen diluted with aCSF (artiﬁcial cerebrospinal ﬂuid) in such a way that
thanol concentration did not exceed 0.006%. 6,7-Dinitroquinoxaline-2,3(1H,4H)-
ione (DNQX) was dissolved in 100% dimethyl sulfoxide (DMSO) and then
iluted with aCSF so that DMSO concentration would not exceed 0.003%.
reatine, creatinine, 3-guanidinopropionic acid (3-GPA), tetrodotoxin (TTX), N-
itro-l-arginine methyl ester (l-NAME), (5R,10S)-(+)5-methyl-10,11-dihydro-5H-
ibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (MK-801), ifenprodil, PMA,
-bromoadenosine-3′ ,5′-cyclic monophosphate (8-Br-cAMP), DNQX, cyclosporin A
nd all other reagents were purchased from Sigma (St. Louis, MO, USA) and solutions
ere prepared in aCSF. Calcineurin assay kit was purchased from Enzo Life Sciences
Farmingdale, NY, USA). To avoid unspeciﬁc actions induced by contaminants, cre-
tine identity and purity was checked by nuclear resonance methods and found to
e greater than 99%.
.2. In situ experiments
Animals were sacriﬁced by decapitation and their hippocampus was immedi-
tely dissected and used for the preparation of slices (400 m thick) with a McIlwain
issue chopper. Slices were suspended in an aCSF containing (in mM):  1.25 NaH2PO4;
2  NaH2CO3; 1.8 MgSO4; 129.0 NaCl; 1.8 CaCl2; 3.5 KCl; 10 d-glucose and 10 Trizma
ase. Afterwards, their contents were aerated with carbogen [95% O2, 5% CO2];
H was  adjusted with carbogen and HCl to 7.4. Osmolarity ranged from 290 to
10 mOsm was checked with an osmometer (ADI instruments, model 3320). The
iability of hippocampal slices was assessed at 0, 30, 60 and 90 min after prepara-
ion by measuring lactate dehydrogenase (LDH) activity with a standard commercial
it  (Labtest, Porto Alegre, RS, Brazil). Considering that the hippocampal slices wereBulletin 88 (2012) 553– 559
viable for more than 60 min after preparation, all experiments were performed
within this time window (data not shown).
The effect of creatine on hippocampal Na+,K+-ATPase activity was investigated
by  incubating 10–12 slices for 30 min  at 37 ◦C with increasing concentrations of
creatine (0, 0.1, 1 or 10 mM). The concentrations of creatine used in the current study
were chosen according to previous biochemical and electrophysiological studies
(Royes et al., 2008; Balestrino et al., 1999; Kass and Lipton, 1986) as well as because
they are comparable to creatine doses used in previous in vivo studies (Oliveira et al.,
2008).  The effect of creatine on hippocampal calcineurin activity was investigated
by  incubating 10–12 slices for 30 min at 37 ◦C with creatine (10 mM).
To  test the effect of creatine metabolite, creatinine, on Na+,K+-ATPase activ-
ity, hippocampal slices were incubated with increasing concentrations (0, 0.1, 1
or  10 mM).  The role of NMDA and AMPA/kainate receptors in the Na+,K+-ATPase
activity alteration elicited by creatine, hippocampal slices were co-incubated with
MK-801 (10 M)  or ifenprodil (3 M)  or DNQX (10 M)  plus creatine (10 mM). In
order to test the participation of the creatine transporter and sodium channel in the
effect exerted by this guanidine compound on Na+,K+-ATPase activity, hippocam-
pal  slices were bathed with 3-GPA (10 mM),  a creatine uptake inhibitor, or TTX
(0.1  M),  a voltage-gated sodium channel blocker, plus creatine (10 mM)  (Lunardi
et  al., 2006). In addition, the involvement of nitric oxide synthase (NOS), PKA/PKC
and calcineurin pathways in the effect exerted by creatine on Na+,K+-ATPase was
tested by incubating hippocampal slices with l-NAME (100 M)  or PMA  (100 nM)
or  8-Br-cAMP (30 M)  or cyclosporin A (200 nM)  plus creatine (10 mM).
After the incubation period, the medium was  discarded and slices were gently
homogenized (7–10 strokes) in ice-cold 10 mM Tris–HCl buffer, pH 7.4, for deter-
mination of Na+,K+-ATPase activity. In a separate set of experiments, designed to
determine whether creatine increased Na+,K+-ATPase activity by directly interact-
ing with the enzyme, creatine (10 mM)  was added directly to the reaction medium
containing hippocampal homogenates.
2.3. Preparation of plasma membrane from hippocampal slices
After the incubation period with creatine (10 mM)  or aCSF, the medium was dis-
carded and the slices were used to prepare plasma membranes according to Mayrand
et  al. (1982), with some modiﬁcations. The hippocampal slices were homogenized
in  a sucrose solution containing (in mM)  250 Sucrose, 10 Tris and 1 EDTA (pH 7.7).
The homogenate was centrifuged at 1000 × g for 10 min  at 4 ◦C to remove excess
debris. The supernatant was removed and centrifuged at 7700 × g for 20 min at
4 ◦C, followed by centrifugation of the supernatant at 7700 × g for 5 min at 4 ◦C. The
supernatant obtained was  centrifuged at 55,000 × g for 30 min  at 4 ◦C. The white
membrane portion of the pellet was retained, discarding the brown pellet. The
white membrane pellet was homogenized in the sucrose solution and then frozen
at  −20 ◦C. Speciﬁc Na+,K+-ATPase activity was measured in this samples of puriﬁed
membranes according to the follow method.
2.4. Na+,K+-ATPase activity measurements
Na+,K+-ATPase activity was measured according to Wyse et al. (2000). Brieﬂy, the
assay medium consisting of 30 mM Tris–HCl buffer, pH 7.4; 0.1 mM EDTA; 50 mM
NaCl; 5 mM KCl; 6 mM MgCl2 and 50 g of protein in the presence or absence of
ouabain (1 mM);  summing up to a ﬁnal volume of 250 L. The reaction was started
by  the addition of adenosine triphosphate to a ﬁnal concentration of 5 mM.  After
30  min  at 37 ◦C, the reaction was stopped by the addition of 50 L of 60% (w/v)
trichloroacetic acid. Saturated substrate concentrations were used and the reaction
was linear with protein (1 mg/mL) and time (30 min). Appropriate controls were
included in the assays for non-enzymatic hydrolysis of ATP. The amount of inor-
ganic phosphate (Pi) released was  quantiﬁed colorimetrically, as described by Fiske
and Subbarow (1925),  using KH2PO4 as a reference standard. Speciﬁc Na+,K+-ATPase
activity was calculated by subtracting the ouabain-insensitive activity from the
overall activity (in the absence of ouabain) and expressed in nmol Pi/mg protein/min.
In  a separate set of experiments, we investigated whether some Na+,K+-ATPase
  isoforms are selectively modulated by creatine. For this purpose, we used a classi-
cal  pharmacological approach based on the isoform-speciﬁc sensitivity to ouabain
(Nishi et al., 1999a). We determined whether creatine increased ouabain-sensitive
ATPase activity using 3 M or 4 mM ouabain (so as to inhibit only the Na+,K+-ATPase
isoforms containing 2 and 3 subunits, or to inhibit every isoform, respectively).
Furthermore, Mg2+-ATPase activity was  measured in the presence of 3 mM ouabain,
according to Munhoz et al. (2005).
2.5. Calcineurin enzymatic activity assay
After the incubation period, the medium was  discarded and slices were gen-
tly  homogenized (7–10 strokes) in calcineurin assay kit buffer. Brieﬂy, calcineurin
activity assays were performed on hippocampal slices homogenates (6 mg/mL)
using a colorimetric calcineurin assay kit according to the manufacturer’s protocol
(Enzo Life Sciences, kit no. BML-AK804). Reactions were stopped after 30 min, and
absorption was  read spectrophotometrically at a wavelength of 620 nm. Calcineurin
activity was expressed in nmol Pi/mg protein/min.
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Table 1
Effect of creatinine (0, 0.1, 1 or 10 mM)  on Na+,K+-ATPase activity of rat hippocampal
slices.
Treatment (mM) Na+,K+-ATPase activity (nmol
Pi/mg protein/min)
Creatinine
aCSF 72.38 ± 4.81
0.1  79.32 ± 4.74
1  78.14 ± 4.79L.M. Rambo et al. / Brain Res
.6.  In vivo experiments
To determine whether the creatine-induced increase on Na+,K+-ATPase activity
lso occurred in vivo, animals were anesthetized with Equithesin (1% phenobar-
ital, 2% magnesium sulfate, 4% chloral hydrate, 42% propylene glycol, and 11%
thanol, 3 mL/kg, i.p.) and placed in a rodent stereotaxic apparatus. Two cannula
ere inserted 1 mm above the CA1 region of the dorsal hippocampus, bilaterally
coordinates relative to bregma: AP 4 mm,  ML  3 mm,  V 2 mm from the dura) under
tereotaxic guidance (Paxinos and Watson, 1986). Chloramphenicol (200 mg/kg,
.p.) was  administered immediately before the surgical procedure. Three days after
he surgical procedure, animals were injected with creatine (5 nmol/0.5 L) and
0  min  thereafter animals were sacriﬁced. The hippocampi were rapidly removed
nd  gently homogenized (7–10 strokes) in ice-cold 10 mM Tris–HCl buffer, pH 7.4
nd Na+,K+-ATPase activity measured as described above. The dose of creatine used
n  this set of experiments was chosen based on previous studies (Oliveira et al., 2008)
nd is comparable to the concentrations of creatine used in the in situ experiments.
.7.  Protein determination
The protein content was colorimetrically determined by the method of Bradford
1976) using bovine serum albumin (1 mg/mL) as a standard.
.8. Statistical analyses
Data were analyzed by a t test, one- or two-way ANOVA, and post hoc analyses
ere carried out by the Student-Newman-Keuls test, when appropriate. Correlation
nalysis was  carried out using the Pearson’s correlation coefﬁcient. A probability of
 < 0.05 was considered signiﬁcant. All data are expressed as mean + SEM.
. Results
Fig. 1A shows the effect of creatine (0, 0.1, 1 or 10 mM)  on
a+,K+-ATPase activity in rat hippocampal slices. Statistical analysis
isclosed that creatine (10 mM)  increases Na+,K+-ATPase activity
n rat hippocampal slices [F(3, 32) = 2.99; P < 0.05, Fig. 1A]. Fig. 1B
hows the effect of creatine (10 mM)  on Na+,K+-ATPase activity of
uriﬁed plasma membranes from hippocampal slices. In puriﬁed
lasma membranes from hippocampal slices creatine also increase
a+,K+-ATPase activity [t(8) = 4.055; P < 0.05, Fig. 1B] in spite of
he higher speciﬁc activity. To determine the effect of creatine
n a cell free system, we added creatine directly to hippocam-
al homogenates. In this experimental condition, creatine (10 mM)
id not alter the Na+,K+-ATPase enzyme activity [F(1, 8) = 0.47;
 > 0.05, Fig. 1C]. Using a classical pharmacological approach based
n the isoform-speciﬁc sensitivity to ouabain concentration (Nishi
t al., 1999a),  we investigated whether some  isoforms of Na+,K+-
TPase are selectively activated by creatine. The results presented
n this report suggest that the stimulatory effect of creatine on
a+,K+-ATPase activity is speciﬁc for 2/3 isoform, since the effect
f creatine on the enzyme activity was not observed in the pres-
nce of 3 M ouabain (a concentration that inhibits 2/3, but not
1 isoforms). Furthermore, such creatine effect was extended to
g2+-ATPase [F(7, 40) = 231.2; P < 0.05, Fig. 1D]. Statistical analy-
is also disclosed that the intra-hippocampal injection of creatine
5 nmol/site) increased Na+,K+-ATPase activity by 21% in the hip-
ocampus [F(1, 18) = 7.03; P < 0.05, Fig. 1F], conﬁrming the results
btained in situ.To test whether the creatine-induced increase in
a+,K+-ATPase activity may  be mediated by trans-cellular creatine
ransport and for its metabolite (creatinine), hippocampal slices
ere incubated with increasing concentrations of creatinine (0,
.1, 1 or 10 mM)  and 3-GPA (10 mM).  In our experimental condi-
ions, creatinine [F(3, 20) = 0.75; P > 0.05] (Table 1) had no effect on
a+,K+-ATPase activity. Accordingly, statistical analysis disclosed
hat the creatine-induced Na+,K+-ATPase activity increase was not
ttenuated by 3-GPA [F(3, 36) = 2.21; P < 0.05, Fig. 2A].
In the present study, we showed that such increase was  attenu-
ted by a voltage-gated sodium channel blocker (TTX, 0.1 M)  [F(3,
4) = 6.56; P < 0.05, Fig. 2B], NMDA antagonist (MK-801, 10 M)
F(3, 20) = 5.75; P < 0.05, Fig. 2C] and the selective antagonist for
R2B subunit (ifenprodil, 3 M)  [F(3, 28) = 6.42; P < 0.05, Fig. 2D].10  80.88 ± 2.17
Data are mean ± SEM for n = 6 in each group.
However, statistical analysis disclosed that the stimulatory effect
exerted by creatine on Na+,K+-ATPase activity was  not reverted by
co-incubation with AMPA/kainate antagonist (DNQX, 10 M)  [F(3,
16) = 0.12; P > 0.05, Fig. 2E]. In addition, although the Na+,K+-ATPase
activity is regulated by NMDA–NOS pathway (Munhoz et al., 2005),
the results presented in this report showed that a non-speciﬁc iso-
form NOS inhibitor (l-NAME, 100 M)  did not alter the studied
enzyme activity [F(3, 24) = 0.82; P > 0.05, Fig. 2F].
The results presented in this report showed that slices pre-
funded with activator of PKC (PMA; 100 nM)  and PKA (8-Br-cAMP;
30 M)  attenuated the creatine-induced increase in Na+,K+-ATPase
activity [F(3, 32) = 4.79; P < 0.05 and F(3, 20) = 4.47; P < 0.05, Fig. 2G
and H, both respectively]. In addition, statistical analysis dis-
closed that the incubation with cyclosporin A (200 nM) attenuated
the stimulatory effect of creatine on Na+,K+-ATPase activity [F(3,
20) = 7.08; P < 0.05, Fig. 2I]. In line of this view, we  demonstrated
that hippocampal slices incubated with creatine had higher both
Na+,K+-ATPase [F(1, 8) = 7.86; P < 0.05, Fig. 3A] and calcineurin [F(1,
8) = 24.16; P < 0.05, Fig. 3B] activities. Moreover, correlation analysis
(Pearson’s) disclosed that Na+,K+-ATPase activity positively corre-
lates with calcineurin activity (r = 0.874; P < 0.05, Fig. 3C).
4. Discussion
In the current study we showed that the incubation with
creatine (10 mM)  increases Na+,K+-ATPase activity in rat hippocam-
pal slices homogenates and plasma membranes and that this
effect seems to be 2/3 isoform-speciﬁc, taking into account the
isoform-speciﬁc sensitivity to ouabain, according to our pharma-
cological approach. Furthermore, the stimulatory effect of this
guanidine compound on Na+,K+-ATPase activity was evidenced
in vivo, after intrahippocampal injection, but not in hippocampal
homogenates of naive animals incubated directly with creatine,
indicating that it requires an intact cellular system. Regarding this
point, it is also possible that tissue homogenizing disrupts criti-
cal anchoring protein linkages between NMDA receptors, kinases,
and Na+,K+-ATPase, resulting in the uncoupling of enzyme modu-
latory components. The results presented in this report disclosed
that NR2B-containing NMDA receptors, voltage-gated Na+ chan-
nels and subsequent calcineurin pathway activation are involved
in the stimulatory effect exerted by this guanidine compound.
Our results also evidenced pharmacologically that the increase of
Na+,K+-ATPase activity elicited by creatine is independent of its
uptake. Besides, such effect possibly involves a mechanism inde-
pendent of changes in the bioenergetic status of the hippocampus,
since creatine needs to be transported into the cell to be phospho-
rylated by creatine kinase and thus to exert its role as an energy
buffer.
The creatine concentrations chosen for concentration/response
curve were based on previous data. It was  reported that exogenous
creatine at high concentration (25 mM)  protects in vitro brain
slices from hypoxic damage (Kass and Lipton, 1986). Incubation of
hippocampal slices with different concentrations of creatine (0.5,
1, 10, 25 mM)  results in a dose-dependent increase in intracellular
556 L.M. Rambo et al. / Brain Research Bulletin 88 (2012) 553– 559
Fig. 1. Effect of creatine (0, 0.1, 1 or 10 mM)  on Na+,K+-ATPase activity of rat hippocampal slices homogenate (A), purifyed plasma membrane from rat hippocampal slices
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ippocampus in vivo (E). Data are mean + SEM for n = 5–10 in each group. *A signiﬁc
hosphocreatine, reaching a plateau with roughly 10 mM crea-
ine, a condition associated with delayed anoxic depolarization
Balestrino et al., 1999). Such creatine concentration range exerts
xcitatory action on hippocampal slices (Royes et al., 2008).
We showed here that creatine (10 mM)  induced an increase
n 2/3 Na+,K+-ATPase activity, by a classical pharmacological
pproach based on the isoform-speciﬁc sensitivity to ouabain,
ithout to employ speciﬁc antibodies for enzyme isoforms. There-
ore, our discussion is based only in our pharmacological data. In
he brain, 2 and 3 isoforms are found in glial and neuronal cells
in same order), contributing to membrane potential generation
ontrol, K+ re-uptake after depolarization (Lecuona et al., 1996;
obasheri et al., 2000; Peng et al., 1997). In this sense, Na+,K+-
TPase is a crucial enzyme involved in the control of neuronal
xcitability and its inhibition may  be associated with several neu-
ological disorders. In line of this view, it has been demonstrated
xperimentally that the Na+,K+-ATPase inhibitor ouabain increases
a2+ entry into brain slices (Fujisawa et al., 1965), and causes
lectrographically recorded seizures in mice (Jamme et al., 1995),
lutamate release by reversal of the Na+-dependent transporter
Li and Stys, 2001), and cell death in rat hippocampi (Lees et al.,
990). Furthermore, a mutation in the 3 isoform – that reduces
a+,K+-ATPase activity about 42% in mice brain – was  associated
ith increased hyperexcitability in the central nervous system,
uggesting that Na+,K+-ATPase may  be involved in control of epilep-
ogenic activity (Clapcote et al., 2009). In this sense, a mutation in
he 2 isoform has been related with sporadic hemiplegic migraine
nd epileptic seizures in humans (Gallanti et al., 2008). Consid-
ring such fact, it is plausible to propose that the stimulation off creatine (10 mM)  on the activity of different Na+,K+-ATPase isoforms (according
ebroventricular injection of creatine (5 nmol/site) on Na+,K+-ATPase activity in rat
fference compared with aCSF group.
2/3 Na+,K+-ATPase elicited by creatine may  be a parallel mecha-
nism involved in the neuroprotective effects of this compound in
neurological diseases.
Although it is believed that the mechanism underlying creatine-
induced neuronal function improvement and neuroprotection
involves enhanced energy storage in a variety of experimental mod-
els of neurological disease (Klein and Ferrante, 2007; Magni et al.,
2007; Royes et al., 2003, 2006), a direct neuromodulatory role
for creatine has also been proposed (Persky and Brazeau, 2001).
In this context, it has been shown that creatine is not only syn-
thesized and taken up by neurons, but also released in such a
manner that it depends on the action potential of the brain cells
(Almeida et al., 2006). This guanidino compound also augments
cerebral blood ﬂow after stroke (Prass et al., 2007) and reduces
inhibitory GABA and glycine responses in mice neurons in cell
culture (De Deyn and Macdonald, 1990). Recently, experimental
ﬁndings from our group suggest that creatine not only seems to
be involved in energy metabolism but may  also play an important
role in the early consolidation of spatial learning in hippocam-
pus with participation of polyamines binding site at the NMDA
receptor (Oliveira et al., 2008). Accordingly, the incubation of hip-
pocampal slices with MK-801 and ifenprodil, respectively selective
antagonists for NMDA and NMDA/NR2B subunit receptors atten-
uated the creatine-induced enzyme activity increase, suggesting
that this effect is dependent of NMDA/NR2B activation. Further-
more, although the glutamate–NMDA–NOS–cGMP–PKG pathway
is known to stimulate 2/3 Na+,K+-ATPase activity (Munhoz et al.,
2005), in our experimental conditions we  did not ﬁnd this pathway
involved in the stimulatory effect of creatine on Na+,K+-ATPase.
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Fig. 2. Effect of 3-GPA (10 mM,  A), TTX (0.1 M,  B), MK-801 (10 M,  C), ifenprodil (3 M, D), DNQX (10 M,  E), l-NAME (100 M,  F), PMA  (100 nM,  G), 8-Br-cAMP (30 M, H)
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and  cyclosporin A (200 nM,  I) on the creatine-induced (10 mM)  increase in Na+,K+-
A  signiﬁcant difference compared with all groups.
In this context, considering that another intracellular pathway
ould be involved in the present stimulatory effect of creatine,
e decided to investigate the involvement of calcineurin and
KA/PKC pathways. This particular experiment data showed that
he stimulatory effect exerted by creatine was attenuated by incu-
ation with cyclosporin A (a calcineurin inhibitor). Furthermore,
he increase of calcineurin activity as well as the positive correlation
etween Na+,K+-ATPase and calcineurin activity in hippocampal
lices incubated with creatine reinforces the assumption that cre-
tine stimulates Na+,K+-ATPase by increasing calcineurin activity.
hese ﬁndings agree with previous observations showing that the
lutamate activation of NMDA receptors followed by calcineurin
eads to stimulation of Na+,K+-ATPase in cerebellar neurons in cul-
ure (Marcaida et al., 1996). Furthermore, it has been proposed
hat the stimulation of the -adrenergic receptor activates the
hosphatase calcineurin, leading to an increase of Na+,K+-ATPase
ctivity in renal tubular cells (Aperia et al., 1992). In the samee activity of rat hippocampal slices. Data are mean + SEM for n = 5–9 in each group.
way, calcineurin-induced Na+,K+-ATPase dephosphorylation is the
mechanism proposed by which norepinephrine induces Na+,K+-
ATPase increase in rat brain (Mallick et al., 2000). In the present
study we  disclosed that the incubation with the PKC activator
(PMA) or the PKA activator (8-Br-cAMP) attenuated the stimulatory
effect exerted by creatine on Na+,K+-ATPase. These data presented
here leads us to speculate that the increase in Na+,K+-ATPase activ-
ity can occur in two ways: directly, by the activation of calcineurin
and the counteraction of the PKC-mediated phosphorylation of the
Ser-23 in the  subunit (Bertuccio et al., 2003, 2007); or indirectly,
by dephosphorylation of the phosphorylation site for PKA (Thr-34)
in the dopamine and cyclic AMP-regulated phosphoprotein (Nishi
et al., 1999b). However, it is merely an speculation and further
studies are needed to clarify this point.
Summing up, we  provide, for the ﬁrst time, pharmacological
evidences of a putative non-energetic pathway by which crea-
tine stimulates Na+,K+-ATPase activity in rat hippocampal slices.
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Big. 3. Effect of creatine (10 mM)  on Na+,K+-ATPase activity (A), calcineurin activity
re  mean + SEM for n = 5 in each group. *A signiﬁcant difference compared with aCS
urthermore, the results presented in this report suggest that
t least some of these effects are mediated by NR2B-containing
MDA receptors, voltage-gated Na+ channels and subsequent cal-
ineurin pathway activation. The activation of this phosphatase,
n turn, counteracts the PKC- and PKA-mediated Na+,K+-ATPase
hosphorylation, leading to the stimulation of 2/3 Na+,K+-ATPase
ctivity. Therefore, in addition to its role as a precursor of
nergy-rich compounds that maintains nearly all cellular function
nd induces neuronal function improvement, the Na+,K+-ATPase
ctivity increase induced by creatine suggests an underlying non-
nergetic role of this guanidine compound in neuronal plasticity
nd possibly in several neurological diseases. However, more stud-
es are required to assess the contribution of this alternative role in
rotection exerted by creatine in neurological diseases that present
ecreased Na+,K+-ATPase activity.
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